<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005622</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-11282</org_study_id>
    <secondary_id>IRB-4189</secondary_id>
    <secondary_id>NCI-G00-1755</secondary_id>
    <nct_id>NCT00005622</nct_id>
  </id_info>
  <brief_title>Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders</brief_title>
  <official_title>Allogeneic Bone Marrow Transplantation Using Closely Matched Related and Unrelated Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy and total-body irradiation before a donor bone marrow&#xD;
      transplant helps stop the growth of cancer cells. It also helps stop the patient's immune&#xD;
      system from rejecting the donor's stem cells. When the stem cells from a related or unrelated&#xD;
      donor, that closely matches the patient's blood, are infused into the patient they may help&#xD;
      the patient's bone marrow to make stem cells, red blood cells, white blood cells, and&#xD;
      platelets.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well donor bone marrow transplant works in&#xD;
      treating patients with leukemia, lymphoma, or nonmalignant hematologic disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the survival of allogeneic bone marrow transplantation using closely matched&#xD;
           related and unrelated donors in patients with malignant or nonmalignant hematological&#xD;
           disorders.&#xD;
&#xD;
        -  Determine the incidence and severity of acute and chronic graft versus host disease with&#xD;
           this treatment regimen in these patients.&#xD;
&#xD;
        -  Determine the relapse rates with this treatment regimen in those patients with malignant&#xD;
           disorders.&#xD;
&#xD;
        -  Determine the incidence and severity of infectious complications associated with this&#xD;
           treatment regimen in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive cyclophosphamide IV over 1 hour on days -6 and -5, total body&#xD;
      radiotherapy on days -3 through 0, and allogeneic bone marrow transplantation on day 0.&#xD;
&#xD;
      Patients with acute lymphocytic leukemia (ALL) receive intrathecal methotrexate at the&#xD;
      beginning of the study. If CNS involvement is documented, patients receive a second dose of&#xD;
      methotrexate 48 hours later followed by oral leucovorin calcium every 6 hours for 4 doses.&#xD;
      Patients with ALL and/or CNS involvement receive intrathecal methotrexate every other week&#xD;
      for 12 weeks after transplant.&#xD;
&#xD;
      Patients with prior CNS involvement receive radiotherapy for 2.5 weeks prior to transplant.&#xD;
      Patients with ALL receive total body radiotherapy for 5 consecutive days prior to transplant.&#xD;
&#xD;
      Patients are followed once a week for 3 months, and then monthly for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study over 6 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1996</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>event free survival (EFS)</measure>
    <time_frame>five year post transplant</time_frame>
    <description>EFS determined by the Kaplan-Meier product limit method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft versus host disease</measure>
    <time_frame>five years post transplant</time_frame>
    <description>incidence and severity of acute and chronic GVHD</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Multiple Myeloma and Malignant Plasma Cell Neoplasms</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <arm_group>
    <arm_group_label>Cy/TBI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>cyclophosphamide and total body irradiation (TBI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Cyclophosphamide is administered at a dose of 60 mg/kg on each of two successive days (Days -6 and -5)</description>
    <arm_group_label>Cy/TBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>TBI</intervention_name>
    <description>FTBI is performed on day -3 through day 0 The total dose of radiation is 1,320 cGy.</description>
    <arm_group_label>Cy/TBI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of one of the following:&#xD;
&#xD;
               -  Acute lymphocytic leukemia (ALL):&#xD;
&#xD;
                    -  Complete remission (CR) 1 - high risk defined as overt CNS involvement or&#xD;
                       poor cytogenetics (additions, deletions, translocations, or multiple&#xD;
                       abnormalities)&#xD;
&#xD;
                    -  CR2&#xD;
&#xD;
                    -  Induction failures&#xD;
&#xD;
                    -  Relapse - patients with at least 10% marrow blasts undergo at least one&#xD;
                       reinduction attempt&#xD;
&#xD;
               -  Acute myelogenous leukemia (AML):&#xD;
&#xD;
                    -  CR1 - high risk defined as poor cytogenetics (deletions, additions, multiple&#xD;
                       abnormalities)&#xD;
&#xD;
                    -  CR2&#xD;
&#xD;
                    -  Induction failures&#xD;
&#xD;
                    -  Relapse - patients with at least 10% marrow blasts undergo at least one&#xD;
                       reinduction attempt&#xD;
&#xD;
               -  Chronic myelogenous leukemia (CML):&#xD;
&#xD;
                    -  Chronic phase (CP) 1&#xD;
&#xD;
                    -  Accelerated phase/CP2 - patients in blast phase must undergo treatment and&#xD;
                       achieve a second chronic phase prior to transplant&#xD;
&#xD;
               -  Chronic lymphocytic leukemia (CLL):&#xD;
&#xD;
                    -  Relapse - any stage; must have received no more than 3 prior regimens&#xD;
&#xD;
               -  Multiple myeloma:&#xD;
&#xD;
                    -  At diagnosis - primary refractory&#xD;
&#xD;
                    -  Relapse (no more than 2) - sensitive disease&#xD;
&#xD;
                    -  Plasma cell leukemia&#xD;
&#xD;
                    -  Inability to achieve a complete remission after autologous transplant (no&#xD;
                       older than 40)&#xD;
&#xD;
               -  Myelodysplasia - all subtypes&#xD;
&#xD;
               -  Myeloproliferative disorders - patients with poor response to medical therapy or&#xD;
                  cytogenetic abnormalities&#xD;
&#xD;
               -  Severe aplastic anemia (SAA):&#xD;
&#xD;
                    -  Very SAA - at diagnosis&#xD;
&#xD;
                    -  SAA - induction therapy&#xD;
&#xD;
          -  Donors must be a phenotypic (6 out of 6) match or a one antigen (A or B) mismatch&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  15 to 50&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 80-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  SGOT and SGPT no greater than 3 times normal&#xD;
&#xD;
          -  PT/PTT normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Left ventricular ejection fraction at least 45%&#xD;
&#xD;
          -  No myocardial infarction within past 6 months&#xD;
&#xD;
          -  No uncontrolled arrhythmias&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  FEV1 at least 50%&#xD;
&#xD;
          -  DLCO at least 50% predicted&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active serious infection&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus or thyroid disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teresa Field, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>May 2, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>October 24, 2012</last_update_submitted>
  <last_update_submitted_qc>October 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>refractory anemia</keyword>
  <keyword>refractory anemia with ringed sideroblasts</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>refractory cytopenia with multilineage dysplasia</keyword>
  <keyword>chronic eosinophilic leukemia</keyword>
  <keyword>chronic neutrophilic leukemia</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL1 negative</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

